WO1999059586A1 - Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes - Google Patents

Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes Download PDF

Info

Publication number
WO1999059586A1
WO1999059586A1 PCT/US1999/011101 US9911101W WO9959586A1 WO 1999059586 A1 WO1999059586 A1 WO 1999059586A1 US 9911101 W US9911101 W US 9911101W WO 9959586 A1 WO9959586 A1 WO 9959586A1
Authority
WO
WIPO (PCT)
Prior art keywords
thiazolidine
dione
benzyl
group
alkyl
Prior art date
Application number
PCT/US1999/011101
Other languages
English (en)
Inventor
Ping H. Wang
Original Assignee
Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of California filed Critical Regents Of The University Of California
Priority to AU40052/99A priority Critical patent/AU4005299A/en
Publication of WO1999059586A1 publication Critical patent/WO1999059586A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Definitions

  • the present application concerns cardiology and more specifically pharmacological treatments for myocardial infarctions.
  • agents which exhibit beneficial effects in experimental models of myocardial stunning, including the antioxidant cyanidanol, the iron chelator l,2-dimethyl-3-hydroxy-4-pyridone and a series of imidazol-2- thiones.
  • Agents which inhibit functional responses of neutrophils, thromboxane synthetase or act as thromboxane receptor antagonists also exhibit beneficial effect in experimental models of myocardial ischemia.
  • R ]9 is alkyl, cycloalkyl, heterocyclyl, aryl or substituted aryl with one or more substituents, selected from alkyl, alkoxy, haloalkyl, halogens, hydroxy and acyloxy groups;
  • R 20 is hydrogen, alkyl, alkoxy, halogen and K is as defined above for structure (Via);
  • R 21 and R ⁇ are the same or different and each represents hydrogen or alkyl
  • R 23 represents hydrogen, alkyl, an acyl group, alkoxycarbonyl group or an aralkyloxy carbonyl group
  • R 24 and R 25 are the same or different and each represents hydrogen, alkyl or alkoxy or R 24 and R 25 together represent an alkylenedioxy group, wherein the alkylene portion is methylene and ethylene.
  • polymethylene group optional substituents for the polymethylene group being selected from alkyl or aryl or adjacent substituents together with the methylene carbon atoms to which they are attached form a substituted or unsubstituted phenylene group.
  • alkyl groups include the methyl, ethyl, propyl, 2-propyl, butyl, 2-methylpropyl, 2-butyl, 2-methyl-2-propyl, pentyl, 2-pentyl, 3-pentyl, 2-methylbutyl, 3-methylbutyl, 1, 1-dimethylpropyl, 1,2- dimethylpropyl, 2,2-dimethyipropyl, hexyl, 2-hexyl, 3-hexyl, 2-methyl-pentyl, 3- methylpentyl, 4-methylpentyl, 1, 1 -dimethyl-butyl, 1,2-dimethylbutyl, 1,3- dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3, 3 -dimethyl butyl, 1, 1,2- trimethylpropyl, 1 ,2 ,2-trimethylpropyl, heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 3,
  • heterocyclic group 10 carbon atoms and having 1 to 4 heteroatoms selected from O, S, NH and N- alkyl, where alkyl is as described earlier.
  • heterocyclic group include furyl, thienyl, pyrrolyl, pyrazolyl, pyridyl, indolyl, oxazolyl, thiazolyl, imidazolyl, indolyl, pyrimidinyl, morpholinyl, piperidinyl, benzoxazolyl, benzothiazolyl and purinyl, such as adenylyl, which may be optionally substituted with one or more substiments selected from substiments (a) described above.
  • the alkyl group R 8 may be a straight-chain or branched alkyl of 1 to 10 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, 2- methylpropyl, 2-mefhyl-2-propyl, butyl, 2-butyl, pentyl, hexyl, octyl, decyl;
  • the cycloalkyl group R 8 may be a cycloalkyl group of 3 to 7 carbon atoms, such as cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl;
  • the phenylalkyl group R 8 may be a phenylalkyl group of 7 to 11 carbon atoms such as benzyl and phenethyl.
  • substiments may have 1 to 3 substiments in optional positions on the respective rings.
  • lower alkyls e.g. methyl, ethyl, etc
  • lower alkoxy groups e.g. methoxy, ethoxy, etc.
  • halogens e.g. fluorine, chlorine, bromine, etc.
  • oxo hydroxyl and its acyl derivatives.
  • the thiazolidine- and oxazolidine-2, 4-diones of the present invention are clinically administered to mammals, including humans, via either the oral, sublingual, rectal, vaginal, nasal, transdermal, subcutaneous, intramuscular, pulmonary or the intravenous route. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absorption following oral administration is impaired or slow to reach therapeutically efficacious levels, as by disease or other abnormality, it is essential that the drug be administered parenterally.
  • the dosage forms and modes of administration described herein are also useful for carrying out the method of the present invention.
  • the dosage is in the range of about 0.10 to about 50 mg/kg body weight of the subject per day, preferably about 0.10 to about 10 mg/kg body weight per day administered singly or as a divided dose.
  • the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage. This will vary according to the particular compound employed and with the subject being treated.

Abstract

Il a été démontré que des dérivés antidiabétiques de thiazolidine et d'oxazolidine (glitazones) produisent de nouveaux effets sur l'apoptose des cardiomyocytes. Ces substances sont capables de diminuer fortement l'apoptose au moyen d'un processus qui n'est pas dépendant de Caspase 3. L'ajout de IGF1 contribue à freiner l'apoptose. Il est recommandé d'administrer, au commencement d'un infarctus du myocarde, des glitazones seules ou des glitazones plus IGF1 et de continuer ce traitement pendant la convalescence, de manière à réduire l'état pathologique et à empêcher un remodelage défavorable du myocarde.
PCT/US1999/011101 1998-05-19 1999-05-19 Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes WO1999059586A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40052/99A AU4005299A (en) 1998-05-19 1999-05-19 Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8603098P 1998-05-19 1998-05-19
US60/086,030 1998-05-19
US8720498P 1998-05-28 1998-05-28
US60/087,204 1998-05-28

Publications (1)

Publication Number Publication Date
WO1999059586A1 true WO1999059586A1 (fr) 1999-11-25

Family

ID=26774281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011101 WO1999059586A1 (fr) 1998-05-19 1999-05-19 Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes

Country Status (2)

Country Link
AU (1) AU4005299A (fr)
WO (1) WO1999059586A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004889A1 (fr) * 1998-07-21 2000-02-03 Smithkline Beecham Plc Utilisation d'un activateur d'assimilation du glucose pour la reduction des lesions cardiaques d'origine ischemique
WO2000004890A1 (fr) * 1998-07-21 2000-02-03 Smithkline Beecham P.L.C. Utilisation d'un activateur d'assimilation du glucose pour reduire l'apoptose
WO2000043007A1 (fr) * 1999-01-19 2000-07-27 Sankyo Company, Limited Compositions médicinales à base de troglitazone inhibitrices de l'apoptose
WO2001095906A1 (fr) * 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Traitement et prevention des etats associes a l'insulino-resistance cardiaque
WO2002051409A1 (fr) * 2000-12-22 2002-07-04 Geron Corporation Inhibiteurs de la telomerase et leurs procedes d'utilisation
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
EP1382336A1 (fr) * 2001-04-25 2004-01-21 Takeda Chemical Industries, Ltd. Promoteurs d'expression d'abc
JP2004505960A (ja) * 2000-08-08 2004-02-26 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 非イミダゾールアリールオキシアルキルアミン
JP2005538188A (ja) * 2002-07-10 2005-12-15 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ アゾリジノン−ビニル縮合−ベンゼン誘導体
WO2006044503A2 (fr) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Composes pour la suppression de mutations non-sens et procedes d'utilisation associes
US7094807B2 (en) 2002-11-19 2006-08-22 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and related compounds; inhibitors of viral replication
WO2007078523A2 (fr) * 2005-12-15 2007-07-12 Astrazeneca Ab Composes d'oxazolidinone et leur utilisation en tant que potentialisateurs de recepteur de glutamate metabotropique
US7365068B2 (en) 2004-05-18 2008-04-29 Achillion Pharmaceuticals, Inc. Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
US7674792B2 (en) 2005-06-08 2010-03-09 Glaxosmithkline Llc 5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
US7767701B2 (en) 2002-11-22 2010-08-03 Glaxosmithkline Llc Chemical compounds
US8138347B2 (en) 2007-05-18 2012-03-20 Glaxosmithkline Llc Quinoline derivatives as PI3 kinase inhibitors
CN103992313A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
US11459319B2 (en) 2014-08-11 2022-10-04 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US11897871B1 (en) 2021-06-14 2024-02-13 Scorpion Therapeutics, Inc. Methods for treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5478851A (en) * 1990-10-30 1995-12-26 Beecham Group Plc Dioxothiazolidine compounds
US5602133A (en) * 1993-09-15 1997-02-11 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478851A (en) * 1990-10-30 1995-12-26 Beecham Group Plc Dioxothiazolidine compounds
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5602133A (en) * 1993-09-15 1997-02-11 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699889B2 (en) 1998-07-21 2004-03-02 Smithkline Beecham P.L.C. Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
EP1523980A3 (fr) * 1998-07-21 2009-03-18 Smithkline Beecham Plc Utilisation d'un activateur d'assimilation du glucose pour la réduction des lésions cardiaques d'origine ischémique
WO2000004889A1 (fr) * 1998-07-21 2000-02-03 Smithkline Beecham Plc Utilisation d'un activateur d'assimilation du glucose pour la reduction des lesions cardiaques d'origine ischemique
AP1416A (en) * 1998-07-21 2005-06-13 Smithkline Beecham Plc Uses of glucose uptake enhancer for reducing post-ischmemic injury of the heart.
WO2000004890A1 (fr) * 1998-07-21 2000-02-03 Smithkline Beecham P.L.C. Utilisation d'un activateur d'assimilation du glucose pour reduire l'apoptose
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
EP1523980A2 (fr) * 1998-07-21 2005-04-20 Smithkline Beecham Plc Utilisation d'un activateur d'assimilation du glucose pour la réduction des lésions cardiaques d'origine ischémique
WO2000043007A1 (fr) * 1999-01-19 2000-07-27 Sankyo Company, Limited Compositions médicinales à base de troglitazone inhibitrices de l'apoptose
WO2001095906A1 (fr) * 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Traitement et prevention des etats associes a l'insulino-resistance cardiaque
JP2004505960A (ja) * 2000-08-08 2004-02-26 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 非イミダゾールアリールオキシアルキルアミン
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002051409A1 (fr) * 2000-12-22 2002-07-04 Geron Corporation Inhibiteurs de la telomerase et leurs procedes d'utilisation
EP1382336A1 (fr) * 2001-04-25 2004-01-21 Takeda Chemical Industries, Ltd. Promoteurs d'expression d'abc
EP1382336B1 (fr) * 2001-04-25 2010-09-08 Takeda Pharmaceutical Company Limited Utilisation du promoteur d'expression d'abc pioglitazone pour le traitement de l'arteriosclerose obliterans
JP4782564B2 (ja) * 2002-07-10 2011-09-28 メルク セローノ ソシエテ アノニム アゾリジノン−ビニル縮合−ベンゼン誘導体
JP2005538188A (ja) * 2002-07-10 2005-12-15 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ アゾリジノン−ビニル縮合−ベンゼン誘導体
US7094807B2 (en) 2002-11-19 2006-08-22 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and related compounds; inhibitors of viral replication
US7476686B2 (en) 2002-11-19 2009-01-13 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and related compounds; inhibitors of viral replication
US7767701B2 (en) 2002-11-22 2010-08-03 Glaxosmithkline Llc Chemical compounds
US7767706B2 (en) 2004-05-18 2010-08-03 Achillion Pharmaceuticals, Inc. Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7365068B2 (en) 2004-05-18 2008-04-29 Achillion Pharmaceuticals, Inc. Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006044503A3 (fr) * 2004-10-13 2006-07-06 Ptc Therapeutics Inc Composes pour la suppression de mutations non-sens et procedes d'utilisation associes
WO2006044503A2 (fr) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Composes pour la suppression de mutations non-sens et procedes d'utilisation associes
US7674792B2 (en) 2005-06-08 2010-03-09 Glaxosmithkline Llc 5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
WO2007078523A2 (fr) * 2005-12-15 2007-07-12 Astrazeneca Ab Composes d'oxazolidinone et leur utilisation en tant que potentialisateurs de recepteur de glutamate metabotropique
US7816354B2 (en) 2005-12-15 2010-10-19 Astrazeneca Ab Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
JP2009519929A (ja) * 2005-12-15 2009-05-21 アストラゼネカ アクチボラグ オキサゾリジノン化合物及び代謝型グルタミン酸レセプター増強剤としてのそれらの使用
WO2007078523A3 (fr) * 2005-12-15 2007-11-15 Astrazeneca Ab Composes d'oxazolidinone et leur utilisation en tant que potentialisateurs de recepteur de glutamate metabotropique
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7632841B2 (en) 2006-05-09 2009-12-15 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
US8138347B2 (en) 2007-05-18 2012-03-20 Glaxosmithkline Llc Quinoline derivatives as PI3 kinase inhibitors
US8404837B2 (en) 2007-05-18 2013-03-26 Glaxosmithkline Llc Quinoline derivatives as P13 kinase inhibitors
US8633187B2 (en) 2007-05-18 2014-01-21 Glaxosmithkline Llc Quinoline derivatives as PI3 kinase inhibitors
US8785433B2 (en) 2007-05-18 2014-07-22 Glaxosmithkline Llc Quinoline derivatives as PI3 kinase inhibitors
CN103992313A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途
US11459319B2 (en) 2014-08-11 2022-10-04 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
US10851095B2 (en) 2014-12-31 2020-12-01 Angion Biomedica Corp. Methods and agents for treating disease
US11434234B2 (en) 2014-12-31 2022-09-06 Angion Biomedica Corp. Methods and agents for treating disease
US11897871B1 (en) 2021-06-14 2024-02-13 Scorpion Therapeutics, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
AU4005299A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
WO1999059586A1 (fr) Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes
EP0719143B1 (fr) Utilisation de derives de thiazolidinedione et d'agents anti-hyperglycemiants apparentes pour le traitement des etats pathologiques risquant d'evoluer en diabete sucre non insulinodependant
US7008956B2 (en) p53 inhibitors and therapeutic use of the same
RU2190425C2 (ru) Способ и композиция для лечения и предупреждения гиперурикемии
KR970001322A (ko) 당뇨병 저해제로서의 치환 n-[인돌-2-카보닐]-글리신아미드 및 유도체
AU706947B2 (en) Use of thiazolidinediones to prevent or delay onset of NIDDM
KR101206319B1 (ko) 티아졸 유도체를 포함하는 수성 조성물
RU2001127082A (ru) Производные аминов
JPH08509486A (ja) アテローム性動脈硬化症および食事障害の治療についてのチアゾリジンジオンの使用
KR20100096094A (ko) 백내장 처치를 위한 의약 조성물
CA2200126C (fr) Traitement et prophylaxie de la pancreatite
KR20000023719A (ko) 렙틴 저항증의 신규 치료 방법
Reddy et al. Novel euglycemic and hypolipidemic agents: Part-2 antioxidant moiety as structural motif
AU710249B2 (en) Autoimmune disease therapeutic agent
JP2013163701A (ja) 低酸素または虚血に伴う眼疾患用組成物
KR19990036290A (ko) 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
WO1997018811A1 (fr) Procede de traitement de dystrophie myotonique
JP3968388B2 (ja) 膵炎治療剤
JPH11335298A (ja) 白血病治療剤
AU750615B2 (en) Use of thiazolidinediones to prevent or delay onset of NIDDM
AU749416B2 (en) Use of thiazolidinediones to prevent or delay onset of NIDDM
JP2004513923A (ja) ある種のインスリン感作剤またはｐｐａｒ−ガンマアゴニストの新規使用
CA2423945A1 (fr) Substance retardant les secretions de muqueuses des voies aeriennes
WO2000007582A2 (fr) Utilisation de derives de thiazolidinedione pour le traitement ou la prevention de cataractes
JPH11255669A (ja) 高尿酸血症治療剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase